ESTRO 2024 - Abstract Book

S432

Brachytherapy - Urology

ESTRO 2024

and proximal seminal vesicles following EBRT. Under general anesthesia, HDR BT was performed real-time and intraoperatively, guided by trans-rectal ultrasound imaging for needle insertion and dosimetry (Elekta Oncentra® Prostate). Toxicity was prospectively evaluated according to CTCAE v4.0 scale.

Results:

With a median follow-up of 51 months, 41 patients developed biochemical failure. Of these, 32 had a clinical relapse (29 systemic relapses, and 3 local recurrences). 4-year actuarial biochemical progression free survival (PFS) was 95,2%; 96,0% for distant progression free survival (dPFS); 99,7% for cancer specific survival (CSS) and 93.7% for overall survival (OS). Early genitourinary (GU) G2 toxicity was observed in 20.14% of patients. Early gastrointestinal (GI) G2 toxicity was found in 4.17%. No G≥3 early toxicity was observed.Late GU toxicity was: G0 64,57%, G1 17,85%, G2 15,76%, G3 1.81%. 17 patients (2.37%) developed urethral stenosis. Late GI toxicity was: G0 86,75%, G1 11,58%, G2 1,67%. No G≥3 GI toxicity was reported.

Conclusion:

Single dose HDR as a boost to EBRT is a safe and effective approach for intermediate-risk and high-risk pCa, with an excellent tolerance in terms of early and late toxicity.

Keywords: Brachytherapy, prostate cancer.